SCHEMBL3542997

SCHEMBL3542997

CCOC(=O)[C@H]1CC[C@H](Oc2ccc(N)cc2)CC1

nearest known ligand 0.53

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
POLB P06746 2/20 0.53
LMNA P02545 1/20 0.46
CYP1A2 P05177 1/20 0.46
CYP3A4 P08684 1/20 0.46
MAOA P21397 1/20 0.46
KMT2A Q03164 4/20 0.46
PKM P14618 1/20 0.46
LGMN Q99538 1/20 0.46
HSD11B1 P28845 1/20 0.45
KCNH2 Q12809 2/20 0.44
MEN1 O00255 3/20 0.44
SHMT2 P34897 1/20 0.44
GAA P10253 2/20 0.43
ALDH1A1 P00352 2/20 0.43
NPC1 O15118 1/20 0.43
RAB9A P51151 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
TDP1 Q9NUW8 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3412798 1.00 POLB (0.53) POLBLMNACYP1A2CYP3A4MAOA
SCHEMBL3412804 1.00 POLB (0.53) POLBLMNACYP1A2CYP3A4MAOA
SCHEMBL5517458 0.87 POLB (0.52) POLBKMT2APKMMEN1ALDH1A1
SCHEMBL5321162 0.87 KMT2A (0.57) POLBLMNAKMT2APKMHSD11B1
SCHEMBL10148089 0.87 POLB (0.52) POLBKMT2APKMMEN1ALDH1A1
SCHEMBL5523536 0.87 MEN1 (0.59) POLBLMNAKMT2AMEN1ALDH1A1
SCHEMBL30929539 0.86 ALDH1A1 (0.54) POLBKMT2APKMMEN1ALDH1A1
SCHEMBL1749787 0.86 ALDH1A1 (0.54) POLBKMT2APKMMEN1ALDH1A1
SCHEMBL241349 0.85 POLB (0.57) POLBLMNAKMT2APKMALDH1A1
SCHEMBL10147939 0.85 POLB (0.57) POLBLMNAKMT2APKMALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100317653-A1 OXADIAZOLE DERIVATIVES AS DGAT INHIBITORS ASTRAZENECA AB (SE) 2010-12-16 US disclosed
US-20100317653-A1 OXADIAZOLE DERIVATIVES AS DGAT INHIBITORS ASTRAZENECA AB (SE) 2010-12-16 US disclosed
US-20100317653-A1 OXADIAZOLE DERIVATIVES AS DGAT INHIBITORS ASTRAZENECA AB (SE) 2010-12-16 US disclosed
US-7795283-B2 Oxadiazole derivative as DGAT inhibitors ASTRAZENECA AB (SE) 2010-09-14 US disclosed
US-7795283-B2 Oxadiazole derivative as DGAT inhibitors ASTRAZENECA AB (SE) 2010-09-14 US disclosed
US-7795283-B2 Oxadiazole derivative as DGAT inhibitors ASTRAZENECA AB (SE) 2010-09-14 US disclosed
US-20080096874-A1 Oxadiazole Derivative as Dgat Inhibitors ASTRAZENECA AB (SE) 2008-04-24 US disclosed
US-20080096874-A1 Oxadiazole Derivative as Dgat Inhibitors ASTRAZENECA AB (SE) 2008-04-24 US disclosed
US-20080096874-A1 Oxadiazole Derivative as Dgat Inhibitors ASTRAZENECA AB (SE) 2008-04-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100317653-A1 OXADIAZOLE DERIVATIVES AS DGAT INHIBITORS DGAT1, DGAT2, GPR119 POLB 1231/4885LMNA 3296/4885CYP1A2 334/4885
US-20080096874-A1 Oxadiazole Derivative as Dgat Inhibitors DGAT1, DGAT2, GPR119 POLB 1483/4885LMNA 3477/4885CYP1A2 353/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.